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SUMMARY
We present a case of a 38+1 weeks pregnant patient 
(G1P0) with a proven COVID-19 infection, who was 
planned for induction of labour because of pre- existent 
hypertension, systemic lupus erythematosus, respiratory 
problem of coughing and mild dyspnoea without fever 
during the COVID-19 pandemic in March 2020. To 
estimate the risk of vertical transmission of Severe Acute 
Respiratory Syndrome CoronaVirus 2 (SARS- CoV-2) 
during labour and delivery, we collected oropharyngeal, 
vaginal, urinary, placental and neonatal PCRs for SARS- 
CoV-2 during the period of admission. All PCRs, except 
for the oropharyngeal, were negative and vertical 
transmission was not observed. Labour and delivery 
were uncomplicated and the patient and neonate were 
discharged the next day. We give a short overview of the 
known literature about SARS- CoV-2- related infection 
during pregnancy, delivery and outcome of the neonate.
BACKGROUND
The pandemic, COVID-19, caused by the novel 
coronavirus SARS- CoV-2, originating from 
the Wuhan region of China, has spread rapidly 
throughout the world, including the Netherlands.1 2 
COVID-19 pneumonia is a highly infectious disease 
and the ongoing outbreak has been declared a global 
public health emergency.1 In the Netherlands, the 
first COVID-19 patient was confirmed on the 27 
February 2020. By the end of March 2020 in the 
Netherlands, 10 866 infected persons have been 
identified, of whom 3483 have been admitted to a 
hospital, more than 800 are currently admitted to 
an Intensive Care Unit (ICU) and 771 people died 
after COVID-19 confirmed infection.3
Due to the adaptive physiological and anatom-
ical changes combined with the immunosuppressive 
state of pregnancy, pregnant women, in general, are 
prone for airway pathogens and pneumonia.4
Little is known about COVID-19 and pregnancy. 
So far, worldwide results have shown that clinical 
characteristics as well as CT imaging results of 
COVID-19 infection in pregnant women seem to 
be similar to non- pregnant adults.5 6 With the recent 
outbreak of the Zika virus in mind, we should be 
aware that new viruses can cross the placenta and 
cause congenital disease.7 So far, there seems to 
be limited evidence for vertical transmission of 
SARS- CoV-2 in pregnant patients.5 8 Schwartz et al 
described no vertical transmission in 38 pregnant 
women with COVID-19 and their neonates using 
PCR analyses.9 Unlike previous Middle East Respi-
ratory Syndrome (MERS) and SARS infections in 
pregnant women, limited maternal deaths have 
been ascribed to COVID-19.9 10
With this case report, we aim to contribute to the 
evidence of the absence of transplacental and intra-
uterine transmission of SARS- CoV-2. We hereby 
report the outcome, management and investigation 
into the vertical transmission of a COVID-19 infec-
tion in a pregnant woman with pre- existent hyper-
tension and systemic lupus erythematosus (SLE).
CASE PRESENTATION
In March 2020, a 31- year- old patient, G1P0, 
amenorrhea of 38+1 weeks, was scheduled for 
induction of labour because of pre- existent hyper-
tension combined with a stable SLE with normal 
kidney function. Tests for Sjogrens Syndrome anti-
bodies (SSA and SSB) were negative. The patient 
used methyldopa, prednisolone and azathioprine 
as prescribed medication. To reduce the risk of 
pre- eclampsia, acetylsalicylic acid was prescribed 
according to local protocol until 36 weeks of preg-
nancy.11 Fetal biometry was within normal range 
throughout pregnancy (antenatal ultrasounds for 
fetal biometrical parameters were performed at 28, 
30, 34 and 36 weeks of gestation) with a continuous 
estimated fetal weight around the 16th percentile.
Due to the development of the progressive 
problem of coughing, the patient contacted our 
outpatient clinic before the scheduled induction 
of labour. Her history mentioned the daily use of 
prednisolone for SLE, did not reveal recent fever or 
having visited a known high- risk COVID-19 region 
or came in contact with people with a confirmed 
SARS- CoV-2 infection. After consulting the micro-
biologist, a PCR for SARS- CoV-2 was performed 
following the national protocol by collecting an 
oropharyngeal sample. The following day the result 
of the test was positive. To prevent further poten-
tial maternal respiratory distress, we decided to 
proceed with the scheduled induction of labour.
After a multidisciplinary consultation, the patient 
was admitted into an isolated zone on the delivery 
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On admission, physical examination revealed a temperature of 
37.2°C, heart rate of 82 beats/min, blood pressure of 141/88 mm 
Hg, transcutaneous saturation of 99% by a FiO2 0.21, with a 
respiratory rate of 12 breaths/min. Lung auscultation revealed 
no abnormal breath sounds. Laboratory findings were normal 
with a C- reactive protein of 14 mg/L, leucocytes of 6.5×109/L, 
haemoglobin of 119.2 g/L, thrombocytes of 192×109/L, neutro-
phils of 5.63×109/L, lymphocytes of 0.22×109/L, monocytes 
of 0.59×109/L, creatinine of 38 µmol/L, estimated Glomerular 
Filtration Rate (eFGR) of >90 mL/min, uric acid of 0.18 mmol/L, 
Alanine aminotransferase (ALAT) of 20 U/L and Lactate dehy-
drogenase (LDH) of 203 U/L. After vaginal examination, a 
Foley catheter with 50cc of sterile water was placed intracer-
vical to induce labour after which the patient went into labour. 
The patient received epidural analgesia to prevent maternal 
exhaustion and to have epidural access for extra analgesia in 
case of an emergency situation. Hereafter, the membranes 
were artificially broken and clear amniotic fluid was drained. 
Augmentation of labour by the administration of oxytocin was 
performed following local protocol until sufficient contractions 
(3–4 per 10 min) were established.12 A corticosteroid stress dose 
scheme was started following local protocol (100 mg in 30 min 
continued by 8.3 mg/hour until 8 hours post partum) because 
of the long- term systemic use of prednisolone with possible 
suppression of the hypothalamic–pituitary–adrenal axis.13 Two 
hours after artificial rupture of membranes, she progressed to 
8 cm of dilation with the fetal head presenting at fetal station 
−3. We observed normal fetal heart tracing with stable maternal 
haemodynamic and respiratory parameters. One hour later the 
patient progressed into the second stage of labour. After 20 min, 
she delivered a daughter with an Apgar score of 9/10 at 5 and 
10 min, respectively, an arterial umbilical pH level of 7.19 and 
a birth weight of 2880 g (30th percentile). The third stage of 
labour proceeded without complications.
There was a normal neonatal transitional phase after delivery, 
with no abnormal findings at physical examination. Antenatal 
SSA and SSB antibodies were tested negative and no signs of 
congenital abnormalities were noted. The neonate shared the 
room with both parents. Parents were advised to minimise 
physical contact during the symptomatic period with coughing, 
dyspnoea and/or a temperature above 38°C. During any phys-
ical contact within this period, the mother was advised to wear 
a surgical mask and surgical gloves to prevent transmission of 
SARS- CoV-2. Our patient bottle fed the neonate.
To be able to assess different anatomical compartments 
capable of viral shedding and different moments of possible 
vertical transmission during pregnancy and delivery, PCRs for 
SARS- CoV-2 were sampled. Prior to and directly after artificial 
rupture of membranes, the fornix posterior of the vagina was 
sampled, while a sample of catheter urine was collected during 
delivery. Post partum, both the maternal and the fetal side of 
the placenta were sampled in addition to an oropharyngeal PCR 
sample of the neonate. We were unable to collect a breastmilk 
sample. For the results, see table 1.
Twelve hours after delivery the patient was discharged from 
the hospital in good health and advised to stay isolated at home 
while being symptomatic for at least 14 days or until 24 hours 
had passed without problems.
OUTCOME AND FOLLOW-UP
By using PCR samples for SARS- CoV-2 at different times and 
from different anatomical regions during delivery, we demon-
strate no evidence of vertical transmission of SARS- CoV-2 after 
vaginal birth in an immune- suppressed SARS- CoV-2 positive 
patient with pre- existing hypertension and SLE. All PCR samples 
which could indicate vertical transmission (vaginal, maternal 
urine, maternal and fetal side of the placenta, oropharynx of 
the neonate) were tested negative. One week after delivery the 
patient still reported coughing and episodes of mild dyspnoea. 
There were no signs of neonatal infection with SARS- CoV-2. 
Four- week post partum, all maternal COVID-19- related symp-
toms were gone and there were no signs of a neonatal COVID-19 
infection.
DISCUSSION
We report a term, prelabour, immuno- suppressed pregnant 
women with pre- existent hypertension and SLE who tested posi-
tive for SARS- CoV-2 and gave birth to a healthy female neonate. 
There was no evidence of transplacental or intrapartum trans-
mission of SARS- CoV-2 following induction of labour in combi-
nation with administration of high doses of corticosteroids. An 
uneventful induction of labour, delivery, postpartum and post-
natal course was observed.
During the course of the COVID-19 infection, several deci-
sions had to be made based on the, at that moment, sparse avail-
able literature about COVID-19 and delivery. First, we decided to 
continue with the scheduled induction of labour, since she was at 
term with only mild respiratory symptoms, but at risk for respi-
ratory insufficiency because of her immunocompromised state 
and the concomitant SARS- CoV-2 infection. Because of a lack 
of evidence of contra- indication for corticosteroids in patients 
with COVID-19 without respiratory insufficiency balanced 
against the known risk of an adrenal crisis without supportive 
therapy, we decided to provide our patient with a stress scheme 
of corticosteroids during the induction of labour.14 Due to the 
immunosuppressive medication during pregnancy and delivery, 
we argued for a possible higher risk of vertical transmission. The 
transplacental viral transmission was suggested by Dong et al 
because of the detection of elevated neonatal IgM and IgG anti-
bodies directly post partum.15 This suggests vertical transmission 
and fetal infection since IgM antibodies cannot be transferred 
over the placenta. However, the reliability of IgM assays has 
been questioned.16 Depending on the routes and mechanism of 
intrauterine infection, further risk assessment can be made. If the 
transplacental transmission can occur, follow- up of fetal devel-
opment after infection should be recommended. Viral shed-
ding in diverse anatomical compartments (vaginal discharge, 
faeces, urine, amniotic fluid and haematogenous/placenta) could 
lead to fetal or neonatal infection during pregnancy, labour or 
delivery with possible consequences for the mode of delivery. 
Table 1 PCR sampling for COVID-19 during different stages of 
labour
Swab Date Time COVID-19
Maternal oropharyngeal 19-03-2020 09:00, at the 
outpatient clinic
Positive
Vaginal swab before rupture of 
membranes
20-03-2020 18:00 Negative
Vaginal swab after rupture of 
membranes
20-03-2020 22:30 Negative
Maternal urinary swab of catheter 
urine
20-03-2020 23:00 Negative
Placental swab maternal side 20-03-2020 23:45 Negative
Placental swab fetal side 20-03-2020 23:45 Negative
Neonatal oropharyngeal swab 21-03-2020 00.30 Negative
P
rotected by copyright.
















3Grimminck K, et al. BMJ Case Rep 2020;13:e235581. doi:10.1136/bcr-2020-235581
New disease
The limited evidence of vertical transmission is comforting, but 
it is important to determine if and how, at which moments and in 
which situations, vertical transmission can occur. This will allow 
adequate advice for patients at risk and shared decision- making 
concerning delivery mode, antenatal and postnatal follow- up.
Royal College of Obstetricians and Gynaecologists (RCOG) 
guidelines recommend not to separate mother and child, with 
a maternal confirmed COVID-19 infection but to make use of 
adequate personal protective measurements to prevent trans-
mission.17 Mother and child were discharged the next day to 
minimise the risk of spreading SARS- CoV-2 by shortening the 
hospital time. We provided strict instructions about COVID-19- 
related symptoms and when to contact the hospital. To identify 
the routes of and risks for possible vertical transmission during 
pregnancy and delivery, we advise to collect PCR samples for 
SARS- CoV-2 of different anatomical regions and at different 
time points during pregnancy and delivery. Immunoglobu-
lins against SARS- CoV-2 should be tested for in maternal and 
neonatal blood as well as in breast milk after maternal infection.
Importantly, even less is known about the consequences of 
infection with COVID-19 in the first and second trimester of 
pregnancy. Recommendations are made to follow- up pregnant 
patients with COVID-19 because of the possible risk of abor-
tion, premature delivery and fetal growth restriction as seen with 
other viral infections in the first and second trimester.18–20
Learning points
 ► Our case shows an uncomplicated vaginal birth in a 
patient with pre- existent hypertension and systemic lupus 
erythematosus (SLE) using long- term corticosteroids without 
signs of vertical transmission of SARS- CoV-2.
 ► The physical stress of vaginal birth did not influence dyspnoea 
and/or saturation levels in an immune- suppressed patient 
with pre- existent hypertension and SLE.
 ► In the absence of an obstetric or maternal contraindication, 
vaginal birth in COVID-19 patient’s wild mild respiratory 
symptoms can and should be considered.
 ► With personal protection measurements in place, COVID-19- 
positive mother and child should not be separated during the 
postpartum period. These measures may be sufficient to avoid 
horizontal transmission of the newborn as seen in our case.
 ► To interpret the vertical transmission of SARS- CoV-2, PCR 
samples for and immunoglobulins against SARS- CoV-2 should 
be included in the medical workup of pregnant women 
suspected for or with a confirmed COVID-19 infection. The 
same workup should be done for the newborn within the first 
few hours after birth.
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